Wyeth Receives Approvable Letter From FDA For TYGACIL For The Treatment Of Patients With Community Acquired Pneumonia
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for the first-in-class antibiotic TYGACIL(R) (tigecycline) for the treatment of adult patients with community-acquired pneumonia (CAP).
More: continued here